Fallopian Tube Cancer – Pipeline Review, H2 2018 to Witness Huge Growth | Leading Key Players: Bayer AG, BeiGene , Biocon , Boehringer Ingelheim GmbH

November 02 08:01 2018

Fallopian Tube Cancer
HTF Market Intelligence released a new research report of 1103 pages on title ‘Fallopian Tube Cancer – Pipeline Review, H2 2018’ with detailed analysis, forecast and strategies.

The study covers important players such as Bayer AG, BeiGene , Biocon , Boehringer Ingelheim GmbH, Boston Biomedical , Bristol-Myers Squibb , Celgene etc

Request a sample report @ https://www.htfmarketreport.com/sample-report/1442068-fallopian-tube-cancer-pipeline-review-5

HTF’s latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer – Pipeline Review, H2 2018, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights

HTF’s Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 14, 71, 46, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 7 and 1 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=1442068

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

AbbVie Inc
Advenchen Laboratories LLC
AiVita Biomedical Inc
Aldeyra Therapeutics Inc
Altor BioScience Corp
Amgen Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Bayer AG
BeiGene Ltd
Biocon Ltd
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Celgene Corp
Celldex Therapeutics Inc
Celsion Corp
Celyad SA
Clovis Oncology Inc
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
Eli Lilly and Co
EpiThany Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Forty Seven Inc
Gene Techno Science Co Ltd
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc
Immune Design Corp
ImmunoGen Inc
IMV Inc
Innate Pharma SA
InSight Biopharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
MabVax Therapeutics Holdings Inc
Mateon Therapeutics Inc
MaxCyte Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Morphotek Inc
Mycenax Biotech Inc
NewLink Genetics Corp
Novartis AG
NuCana Plc
Oasmia Pharmaceutical AB
OBI Pharma Inc
Omnitura Therapeutics Inc
Oncobiologics Inc
Oncolix Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Prescient Therapeutics Ltd
Protheragen Inc
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rgenix Inc
Rigel Pharmaceuticals Inc
Samyang Holdings Corp
Sanofi
Sanofi Pasteur SA
SELLAS Life Sciences Group Inc
Sotio AS
Sun Pharma Advanced Research Company Ltd
Syndax Pharmaceuticals Inc
Synermore Biologics Co Ltd
TESARO Inc
Tyrogenex Inc (Inactive)
Vascular Biogenics Ltd
Verastem Inc
Vyriad Inc

Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/1442068-fallopian-tube-cancer-pipeline-review-5

Table of Contents
Table of Contents 2
Introduction 6
Fallopian Tube Cancer – Overview 7
Fallopian Tube Cancer – Therapeutics Development 8
Fallopian Tube Cancer – Therapeutics Assessment 25
Fallopian Tube Cancer – Companies Involved in Therapeutics Development 41
Fallopian Tube Cancer – Drug Profiles 85
Fallopian Tube Cancer – Dormant Projects 1070
Fallopian Tube Cancer – Discontinued Products 1074
Fallopian Tube Cancer – Product Development Milestones 1075
Appendix 1086List of Tables
Number of Products under Development for Fallopian Tube Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018

….Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1442068-fallopian-tube-cancer-pipeline-review-5

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Media Contact
Company Name: HTF Market Intelligence Consulting Private Limited
Contact Person: Craig Francis
Email: Send Email
Phone: 2063171218
Address:Unit No. 429, Parsonage Road
City: Edison
State: New Jersey
Country: United States
Website: www.htfmarketreport.com/reports/1442068-fallopian-tube-cancer-pipeline-review-5

  Categories: